tiprankstipranks
MediWound and Teva Amend Settlement Terms
Company Announcements

MediWound and Teva Amend Settlement Terms

Mediwound (MDWD) has released an update.

Don't Miss our Black Friday Offers:

MediWound Ltd. and Teva Pharmaceutical Industries Ltd. have effectively agreed on a second amendment to their 2019 settlement agreement, which will resolve all outstanding issues related to their prior business relationship. This amendment includes a final payment of $4 million from MediWound to Teva, with conditions that include cash payment and setoff arrangements. The updated agreement reaffirms the full and final settlement of claims between the two parties and outlines the tax treatment for the payments.

For further insights into MDWD stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMediWound Advances Enzymatic Therapeutics Amid Financial Shifts
TipRanks Auto-Generated NewsdeskMediWound Advances with FDA Approval and New Funding
TheFlyMediWound reports Q3 EPS (98c), consensus (44c)
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App